Errol Babacan

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

Schlomo Staszewski, Errol Babacan, Christoph Stephan et al. · Journal of Antimicrobial Chemotherapy · 2006 · 33 citations · Full text

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

Nils von Hentig, Errol Babacan, Tessa Lennemann et al. · Journal of Antimicrobial Chemotherapy · 2008 · 31 citations · Full text

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo

Jochen Graff, Nils von Hentig, Karina Kuczka et al. · Journal of Antimicrobial Chemotherapy · 2007 · 21 citations

Pharmacokinetics, Safety and Efficacy of Saquinavir/ Ritonavir 1,000/100 Mg Twice Daily as HIV Type-1 Therapy and Transmission Prophylaxis in Pregnancy

Nils von Hentig, Gabi Nisius, Tessa Lennemann et al. · Antiviral Therapy · 2008 · 21 citations · Full text

Predictive Factors for Response to a Boosted Dual HIV-Protease Inhibitor Therapy with Saquinavir and Lopinavir in Extensively Pre-Treated Patients

Nils von Hentig, Errol Babacan, Schlomo Staszewski et al. · Antiviral Therapy · 2007 · 14 citations · Full text